Literature DB >> 8383924

Screening for disulfiram-induced liver test dysfunction in an inpatient alcoholism program.

C Wright1, R D Moore, D M Grodin, D A Spyker, E V Gill.   

Abstract

The objective of this study was to report the frequency of disulfiram-related elevations of four commonly used hepatic screening chemistries using a retrospective record review design. An inpatient alcoholism program was selected for the setting. Patients who had initial laboratory values within the normal range started daily supervised doses of disulfiram, then underwent follow-up testing after 2 and 4 weeks on the drug. The study population consisted of 108 patients receiving disulfiram and 27 patients who did not receive disulfiram (controls). The four screening serum chemistries performed were aspartate aminotransferase (SGOT), alanine aminotransferase (SGPT), alkaline phosphatase, and gamma-glutamyl transferase. Twenty-seven (25%) of the 108 patients who were taking 250 mg of disulfiram a day for 2 to 4 weeks had disulfiram-related elevations in alanine aminotransferase above the upper limit of normal, as opposed to one elevation in 27 patients (4%) for whom disulfiram was not prescribed. In the 108 patients (with initially normal serum chemistries) who were prescribed disulfiram, 32 were discontinued from the drug at 2 weeks and an additional 11 were discontinued from the drug at 4 weeks because of one or more abnormal serum chemistries. Alanine aminotransferase was the most specific and sensitive indicator of the four screening chemistries performed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8383924     DOI: 10.1111/j.1530-0277.1993.tb00745.x

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  2 in total

Review 1.  Safety issues concerning the use of disulfiram in treating alcohol dependence.

Authors:  J Chick
Journal:  Drug Saf       Date:  1999-05       Impact factor: 5.606

2.  Evaluation of the dopamine β-hydroxylase (DβH) inhibitor nepicastat in participants who meet criteria for cocaine use disorder.

Authors:  Richard De La Garza; Marcy J Bubar; Crystal L Carbone; F Gerard Moeller; Thomas F Newton; Noelle C Anastasio; Tod A Harper; David L Ware; Michael A Fuller; Gaylyn J Holstein; Jason B Jayroe; Stephen I Bandak; Kirsten Z Reiman; Ann C Neale; Lesley B Pickford; Kathryn A Cunningham
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-01-17       Impact factor: 5.067

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.